Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

1.

Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model.

Son WS, Jeong KS, Lim SM, Pae AN.

Bioorg Med Chem Lett. 2019 May 15;29(10):1168-1172. doi: 10.1016/j.bmcl.2019.03.026. Epub 2019 Mar 21.

PMID:
30928197
2.

Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.

Park JH, Ju YH, Choi JW, Song HJ, Jang BK, Woo J, Chun H, Kim HJ, Shin SJ, Yarishkin O, Jo S, Park M, Yeon SK, Kim S, Kim J, Nam MH, Londhe AM, Kim J, Cho SJ, Cho S, Lee C, Hwang SY, Kim SW, Oh SJ, Cho J, Pae AN, Lee CJ, Park KD.

Sci Adv. 2019 Mar 20;5(3):eaav0316. doi: 10.1126/sciadv.aav0316. eCollection 2019 Mar.

3.

Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy.

Choi JW, Kim S, Park JH, Kim HJ, Shin SJ, Kim JW, Woo SY, Lee C, Han SM, Lee J, Pae AN, Han G, Park KD.

J Med Chem. 2019 Jan 24;62(2):811-830. doi: 10.1021/acs.jmedchem.8b01527. Epub 2018 Dec 20.

PMID:
30540174
4.

Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.

Lee JH, El-Damasy AK, Seo SH, Gadhe CG, Pae AN, Jeong N, Hong SS, Keum G.

Bioorg Med Chem. 2018 Nov 15;26(21):5596-5611. doi: 10.1016/j.bmc.2018.10.004. Epub 2018 Oct 9.

PMID:
30385226
5.

Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain.

Yang HK, Son WS, Lim KS, Kim GH, Lim EJ, Gadhe CG, Lee JY, Jeong KS, Lim SM, Pae AN.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):1460-1471. doi: 10.1080/14756366.2018.1513926.

6.

Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease.

Lim JW, Kim SK, Choi SY, Kim DH, Gadhe CG, Lee HN, Kim HJ, Kim J, Cho SJ, Hwang H, Seong J, Jeong KS, Lee JY, Lim SM, Lee JW, Pae AN.

Eur J Med Chem. 2018 Sep 5;157:405-422. doi: 10.1016/j.ejmech.2018.07.071. Epub 2018 Aug 3.

PMID:
30103190
7.

Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of Aβ-induced mPTP opening for Alzheimer's disease.

Elkamhawy A, Park JE, Hassan AHE, Pae AN, Lee J, Paik S, Park BG, Roh EJ.

Eur J Med Chem. 2018 Sep 5;157:268-278. doi: 10.1016/j.ejmech.2018.07.068. Epub 2018 Jul 31.

PMID:
30098482
8.

Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor δ agonist.

Kim DS, Lee J, Londhe AM, Kadayat TM, Joo J, Hwang H, Kim KH, Pae AN, Chin J, Cho SJ, Kang H.

Bioorg Med Chem. 2018 Aug 15;26(15):4382-4389. doi: 10.1016/j.bmc.2018.06.044. Epub 2018 Jul 20.

PMID:
30054191
9.

GRP78-targeted in-silico virtual screening of novel anticancer agents.

Viswanath ANI, Lim JW, Seo SH, Lee JY, Lim SM, Pae AN.

Chem Biol Drug Des. 2018 Aug;92(2):1555-1566. doi: 10.1111/cbdd.13322. Epub 2018 May 31.

PMID:
29718569
10.

A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer.

Fang Z, Han B, Jung KH, Lee JH, El-Damasy AK, Gadhe CG, Kim SJ, Yan HH, Park JH, Lee JE, Kang YW, Pae AN, Keum G, Hong SS.

Cancer Lett. 2018 Jul 10;426:25-36. doi: 10.1016/j.canlet.2018.03.041. Epub 2018 Mar 30.

PMID:
29605512
11.

Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of Aβ-induced mitochondrial dysfunction in Alzheimer's disease.

Elkamhawy A, Park JE, Hassan AHE, Pae AN, Lee J, Park BG, Roh EJ.

Eur J Med Chem. 2018 Jan 20;144:529-543. doi: 10.1016/j.ejmech.2017.12.045. Epub 2017 Dec 14.

PMID:
29288949
12.

Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.

Yeon SK, Choi JW, Park JH, Lee YR, Kim HJ, Shin SJ, Jang BK, Kim S, Bahn YS, Han G, Lee YS, Pae AN, Park KD.

Bioorg Med Chem. 2018 Jan 1;26(1):232-244. doi: 10.1016/j.bmc.2017.11.036. Epub 2017 Nov 24.

PMID:
29198609
13.

Direct interaction with 14-3-3γ promotes surface expression of Best1 channel in astrocyte.

Oh SJ, Woo J, Lee YS, Cho M, Kim E, Cho NC, Park JY, Pae AN, Justin Lee C, Hwang EM.

Mol Brain. 2017 Nov 9;10(1):51. doi: 10.1186/s13041-017-0331-x.

14.

Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.

Farag AK, Elkamhawy A, Londhe AM, Lee KT, Pae AN, Roh EJ.

Eur J Med Chem. 2017 Dec 1;141:657-675. doi: 10.1016/j.ejmech.2017.10.003. Epub 2017 Oct 4.

PMID:
29107425
15.

Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: Neuroprotection against amyloid-β-induced toxicity.

Park JE, Elkamhawy A, Hassan AHE, Pae AN, Lee J, Paik S, Park BG, Roh EJ.

Eur J Med Chem. 2017 Dec 1;141:322-334. doi: 10.1016/j.ejmech.2017.09.043. Epub 2017 Sep 22.

PMID:
29031076
16.

Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.

Kim T, Son WS, Morshed MN, Londhe AM, Jung SY, Park JH, Park WK, Lim SM, Park KD, Cho SJ, Jeong KS, Lee J, Pae AN.

Eur J Med Chem. 2017 Dec 1;141:240-256. doi: 10.1016/j.ejmech.2017.09.033. Epub 2017 Sep 21.

PMID:
29031071
17.

Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in Aβ-induced mitochondrial dysfunction.

Park I, Londhe AM, Lim JW, Park BG, Jung SY, Lee JY, Lim SM, No KT, Lee J, Pae AN.

J Comput Aided Mol Des. 2017 Oct;31(10):929-941. doi: 10.1007/s10822-017-0067-9. Epub 2017 Sep 14.

PMID:
28913661
18.

In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level.

Park I, Hwang YJ, Kim T, Viswanath ANI, Londhe AM, Jung SY, Sim KM, Min SJ, Lee JE, Seong J, Kim YK, No KT, Ryu H, Pae AN.

J Comput Aided Mol Des. 2017 Oct;31(10):877-889. doi: 10.1007/s10822-017-0052-3. Epub 2017 Sep 6.

PMID:
28879500
19.

Identification of Optically Active Pyrimidine Derivatives as Selective 5-HT2C Modulators.

Kim J, Jo H, Lee H, Choo H, Kim HJ, Pae AN, Cho YS, Min SJ.

Molecules. 2017 Aug 26;22(9). pii: E1416. doi: 10.3390/molecules22091416.

20.

In silico-designed novel non-peptidic ABAD LD hot spot mimetics reverse Aβ-induced mitochondrial impairments in vitro.

Viswanath ANI, Kim T, Jung SY, Lim SM, Pae AN.

Chem Biol Drug Des. 2017 Dec;90(6):1041-1055. doi: 10.1111/cbdd.13065. Epub 2017 Jul 27.

PMID:
28660722

Supplemental Content

Loading ...
Support Center